Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tectonic TherapeuticTECX -7.84%14 PB Ratio is 2.92 as of Aug. 13, 2026. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,220 Biotechnology companies, Tectonic Therapeutic ranks worse than 53.11% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tectonic Therapeutic PB Ratio Related Terms
Tectonic Therapeutic PB Ratio Historical Data
* Premium members only.
The historical data trend for Tectonic Therapeutic's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tectonic Therapeutic's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tectonic Therapeutic PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tectonic Therapeutic's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tectonic Therapeutic (TECX) has a PB Ratio of 2.92 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tectonic Therapeutic and its competitors. According to the industry distribution chart, Tectonic Therapeutic ranks #648 out of 1220 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Tectonic Therapeutic's PB Ratio too high?
Tectonic Therapeutic's current PB Ratio is 2.92. The Biotechnology industry median PB Ratio is 2.91. Tectonic Therapeutic's value of 2.92 is 0.5% above this industry median. Based on the distribution chart, Tectonic Therapeutic ranks #648 out of 1220 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's PB Ratio compare to ZVRA and SPRY?
According to the Biotechnology industry distribution chart, Tectonic Therapeutic ranks #648 out of 1220 companies for PB Ratio. This places Tectonic Therapeutic in the lower half of its industry. The industry median PB Ratio is 2.91. Tectonic Therapeutic's value of 2.92 is 0.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tectonic Therapeutic's current PB Ratio of 2.92 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tectonic Therapeutic and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tectonic Therapeutic's current PB Ratio is 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current PB Ratio of 2.92. The current PB Ratio is 2.92 and 0.5% above the Biotechnology industry median of 2.91. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current PB Ratio is 2.92 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score
Get the complete analysis for TECX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECX has been successfully added to your 
